Posted by Michael Wonder on 06 Dec 2019
Alector announces FDA fast track designation granted to AL001 for the treatment of patients with frontotemporal dementia
5 December 2019 - Alector today announced that the U.S. FDA has granted fast track designation for its investigational therapeutic, AL001, for the treatment of patients with frontotemporal dementia carrying specific genetic mutations in the granulin gene.
AL001 is the company’s product candidate currently being evaluated in a Phase 2 trial for the treatment of FTD-GRN and FTD-C9orf72.
